Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trialHannah Cohen, David Isenberg, Maria Ruiz-Castellano et al.|The Lancet Haematology|2016Cited by 404
Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (<i>Br. J. </i><i>Haematol</i><i>.</i> 2012; 157: 47–58): use of direct acting oral anticoagulantsDeepa J. Arachchillage, Keith Gomez, Raza Alikhan et al.|British Journal of Haematology|2020Cited by 81
Guidelines on the investigation and management of antiphospholipid syndromeDeepa J. Arachchillage, Karen Breen, Sean Platton et al.|British Journal of Haematology|2024Cited by 49
Diagnosis and management of heparin‐induced thrombocytopenia: Third editionDeepa J. Arachchillage, Michael Laffan, Jecko Thachil et al.|British Journal of Haematology|2023Cited by 31
Measurement of heparin, direct oral anti‐coagulants and other non‐coumarin anti‐coagulants and their effects on haemostasis assays: A British Society for Haematology GuidelinePeter Baker, Keith Gomez, Deepa J. Arachchillage et al.|British Journal of Haematology|2024Cited by 15